More news articles

Novartis gets EU nod for leukaemia drug Rydapt

The FLT3 inhibitor adds to its US approval in AML

Alnylam takes off on APOLLO trial results

Provides first late-stage evidence on the biotech's gene-silencing platform

UCB’s antiepileptic drug gains new US indication

FDA approves Briviact as a monotherapy to treat POS

FDA approves Medtronic's tablet-controlled pain device

The Intellis system can be programmed via a Samsung's Galaxy S2

Teva's Mark Salyer joins Amarin

Takes up newly-created chief commercial officer role

M3 appoints Simon Walker as director of education

In his new role he will lead the company's educational strategy

With US approval, GSK now needs rapid uptake for COPD triple

Aims to quickly launch the predicted blockbuster to revive its R&D portfolio

NICE says OK to Opdivo for lung cancer via CDF

Comes after BMS drops the price of its PD-1 inhibitor

MSD's Keytruda wins new bladder cancer indication in Europe

Will treat locally advanced or mUC patients

Ljubisav Matejevic joins health IT firm Ascom

He is appointed to central and eastern Europe role

AbbVie and Roche plan Venclexta combo filings in leukaemia

MURANO trial shows the duo’s treatment extends PFS

Teva offloads women's health unit in quickfire deals

The Israeli pharma group is also set to sell its oncology and pain business

Almirall looks to crowdsource new skin health treatments

Launches open innovation platform AlmirallShare

Merck to co-lead new oncology big data alliance

Will work with Project Data Sphere to improve cancer care

CHMP backs maintenance therapy for Tesaro's Zejula

Swiss biotech's PARP inhibitor recommended for approval in ovarian cancer

Neovii Pharmaceuticals promotes Juergen Pohle to CEO

He will take over from Alexandre Sudarskis in January